Effect of bevacizumab in treatment of children with optic pathway glioma.
- Author:
Wan-Shui WU
1
;
Jing-Jing LIU
;
Yan-Ling SUN
;
Shu-Xu DU
;
Chun-De LI
;
Miao LI
;
Si-Qi REN
;
Jin ZHANG
;
Xiao-Jun GONG
;
Li-Ming SUN
Author Information
1. Department of Pediatrics, Beijing Shijitan Hospital Affiliated to Capital Medical University, Beijing 100038, China. sunlm@bjsjth.cn.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Combined Chemotherapy Protocols;
Bevacizumab;
Carboplatin;
Child;
Humans;
Optic Nerve Glioma;
Retrospective Studies;
Vincristine
- From:
Chinese Journal of Contemporary Pediatrics
2019;21(12):1193-1197
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effect of bevacizumab in the treatment of children with optic pathway glioma (OPG).
METHODS:A retrospective analysis was performed for the clinical data of 30 children with OPG who underwent chemotherapy. According to whether bevacizumab was used, they were divided into conventional chemotherapy (carboplatin, vincristine and etoposide) group with 12 children and combined chemotherapy (bevacizumab, carboplatin, vincristine and etoposide) group with 18 children. The children were followed up to 6 months after chemotherapy, and the two groups were compared in terms of visual acuity and tumor size before and after chemotherapy and adverse reactions during chemotherapy.
RESULTS:The combined chemotherapy group had a significantly higher proportion of children achieving tumor regression than the conventional chemotherapy group (P<0.05), while there were no significant differences between the two groups in the proportion of children with improved visual acuity or adverse reactions (P>0.05). No chemotherapy-related death was observed in either group.
CONCLUSIONS:Bevacizumab combined with conventional chemotherapy can effectively reduce tumor size. Compared with conventional chemotherapy, such combination does not increase adverse reactions and can thus become a new direction for the treatment of OPG in children.
